Provision of Computational Biology Support for Research by Melbourne Bioinformatics, MDHS, UoM to a/Prof Scott's Lab of the Walter and Eliza Hall Institute of Medical Research.

PyLazyBam - A pure python lazy BAM parser

Matthew Wakefield

2020-01-01

Pylazybam is a pure python library for reading minimal amounts of information from a BAM format mapped sequence alignment file. It..

Diverse mechanisms of PARP inhibitor resistance in ovarian cancer

MJ Wakefield, K Nesic, O Kondrashova, CL Scott

2019-12-01

RNA-seq of Isolated Chromaffin Cells Highlights the Role of Sex-Linked and Imprinted Genes in Adrenal Medulla Development

WH Chan, M Komada, T Fukushima, EM Southard-Smith, CR Anderson, MJ Wakefield

2019-12-01

Adrenal chromaffin cells and sympathetic neurons synthesize and release catecholamines, and both cell types are derived from neura..

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

O Kondrashova, M Topp, K Nesic, E Lieschke, GY Ho, MI Harrell, GV Zapparoli, A Hadley, R Holian, E Boehm, V Heong, E Sanij, RB Pearson, JJ Krais, N Johnson, O McNally, S Ananda, K Alsop, KJ Hutt, SH Kaufmann

2018-12-01

Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly(ADP-ribose) polymerase inhibi..

Australian Ovarian Cancer Assortment Trial-Allocating ovarian cancer patients into clinical trials based on molecular profiling.

Olga Kondrashova, George Au-Yeung, Leakhena Leas, Gwo-Yaw Ho, Sebastian Lunke, Kathryn Alsop, Clare Scott, Anne Hamilton, Sumitra Ananda, Alison Freimund, Michael Quinn, Orla McNally, Nadia Traficante, Tiffany Cowie, Matthew Wakefield, Arthur Hsu, Alex Dobrovic, Michael Christie, Graham Taylor, David Bowtell

2018-08-01

<jats:title>Abstract</jats:title> <jats:p>Background: The Australian Ovarian Cancer Assortment Trial (ALLOCATE) was..

DNA repair processes are critical mediators of p53-dependent tumor suppression letter

A Janic, LJ Valente, MJ Wakefield, L Di Stefano, L Milla, S Wilcox, H Yang, L Tai, CJ Vandenberg, AJ Kueh, S Mizutani, MS Brennan, RL Schenk, LM Lindqvist, AT Papenfuss, L O'Connor, A Strasser, MJ Herold

2018-07-01

It has long been assumed that p53 suppresses tumor development through induction of apoptosis, possibly with contributions by cell..

Targeting DNA repair: the genome as a potential biomarker

K Nesic, M Wakefield, O Kondrashova, CL Scott, IA McNeish

2018-04-01

Genomic instability and mutations are fundamental aspects of human malignancies, leading to progressive accumulation of the hallma..

Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma

O Kondrashova, M Nguyen, K Shield-Artin, AV Tinker, NNH Teng, MI Harrell, MJ Kuiper, GY Ho, H Barker, M Jasin, R Prakash, EM Kass, MR Sullivan, GJ Brunette, KA Bernstein, RL Coleman, A Floquet, M Friedlander, G Kichenadasse, DM O’Malley

2017-09-01

High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensi..

Genomic Analysis of Mucinous Tumors (GAMUT): Developing Therapeutic Options for Ovarian Carcinomas

K Gorringe, D Cheasley, M Wakefield, Y Antill, I Campbell, C Scott

2017-08-01

Genetically engineered mouse models of proliferative C5 high grade serous ovarian cancer

Clare L Scott, Gwo Y Ho, Elizabeth E Lieschke, Olga Kondrashova, Ronny Drapkin, David Bowtell, Matthew J Wakefield

2017-07-01

<jats:title>Abstract</jats:title> <jats:p>Introduction: High-grade serous ovarian cancer (HGSOC) can be divided int..

Hedgehog inhibition impaired platinum response in high-grade serous ovarian cancer harboring high hedgehog ligand expression and mTOR pathway activation.

Gwo Yaw Ho, Elizabeth Lieschke, Elizabeth Kyran, Kristy Shield-Artin, Olga Kondrashova, Holly Barker, Robert Hollian, Aurelie Cazet, Phuong Thuan, Alex Swarbrick, Orla McNally, David Bowtell, Matthew Wakefield, Clare L Scott

2017-05-20

<jats:p> 5583 </jats:p><jats:p> Background: Elevated Glioma-associated Oncogene Homolog-1 (Gli1) protein expression is associated ..

SurvivalVolume: interactive volume threshold survival graphs

Matthew J. Wakefield

2016-12-14

Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer

K Lin, AV Tinker, O Kondrashova, G Ho, M Wakefield, RL Coleman, DM O'Malley, A Floquet, J Sun, L Maloney, H Giordano, T Harding, M Raponi, IA McNeish, E Swisher, CL Scott

2016-12-01

TREATMENT OF TSC1-DELETED HIGH-GRADE SEROUS OVARIAN CANCER CONFOUNDED BY HEDGEHOG PATHWAY OVEREXPRESSION

Gwo Yaw Ho, Elizabeth Lieschke, Elizabeth Kyran, Kristy Shield-Artin, Olga Kondrashova, Robert Holian, Ankita Singh, Thuan Phuong, Aurelie Cazet, Alex Swarbrick, David Bowtell, Matthew J Wakefield, Clare Scott

2016-11-01

Xenomapper: Mapping reads in a mixed species context

Matthew J. Wakefield

2016-05-22

Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer

K Lin, M wakefield, O Kondrashova, C Scott, G Ho

2016-01-01